Lung Cancer Panel 3 EGFR ALK1 ROS1 MET Genetic Testing
Comprehensive Introduction to Lung Cancer Genetic Testing
The Lung Cancer Panel 3 EGFR ALK1 ROS1 MET represents a cutting-edge molecular diagnostic approach for non-small cell lung cancer (NSCLC) patients. This comprehensive genetic panel examines four crucial biomarkers that have revolutionized lung cancer treatment in recent years. By analyzing these specific genetic alterations, healthcare providers can identify patients who are likely to respond to targeted therapies, transforming the landscape of personalized cancer care.
This advanced testing methodology combines FISH (Fluorescence In Situ Hybridization) and Sanger Sequencing techniques to provide highly accurate results. The integration of multiple detection methods ensures comprehensive coverage of genetic variations, offering clinicians a complete picture of the tumor’s molecular profile for informed treatment decisions.
What This Test Measures and Detects
The Lung Cancer Panel 3 specifically targets four key genetic markers that play critical roles in lung cancer development and progression:
EGFR (Epidermal Growth Factor Receptor) Mutations
- Detects activating mutations in exons 18-21
- Identifies patients eligible for EGFR tyrosine kinase inhibitors
- Helps predict response to targeted therapies like gefitinib and erlotinib
ALK1 (Anaplastic Lymphoma Kinase) Rearrangements
- Screens for ALK gene fusions and rearrangements
- Identifies candidates for ALK inhibitors such as crizotinib
- Detects EML4-ALK fusion variants
ROS1 (ROS Proto-Oncogene 1) Fusions
- Tests for ROS1 gene rearrangements
- Identifies patients who may benefit from ROS1-targeted therapies
- Detects various fusion partners including CD74 and SLC34A2
MET (Mesenchymal-Epithelial Transition) Alterations
- Analyzes MET amplification and exon 14 skipping mutations
- Identifies potential resistance mechanisms to other targeted therapies
- Helps guide treatment with MET inhibitors
Who Should Consider This Genetic Test
This comprehensive lung cancer panel is recommended for patients with:
Clinical Indications
- Newly diagnosed non-small cell lung cancer (adenocarcinoma preferred)
- Advanced or metastatic lung cancer requiring treatment planning
- Progressive disease despite initial therapy
- Family history of lung cancer or genetic predisposition
- Never-smokers or light smokers with lung cancer
Symptoms and Presentation
- Persistent cough or coughing up blood
- Shortness of breath or wheezing
- Chest pain that worsens with deep breathing
- Unexplained weight loss and fatigue
- Recurrent respiratory infections
Significant Benefits of Genetic Testing
Undergoing the Lung Cancer Panel 3 offers numerous advantages for patients and healthcare providers:
Personalized Treatment Planning
- Enables selection of targeted therapies based on genetic profile
- Helps avoid ineffective treatments and unnecessary side effects
- Provides opportunity for clinical trial enrollment
Improved Clinical Outcomes
- Higher response rates with matched targeted therapies
- Longer progression-free survival in biomarker-positive patients
- Better quality of life through reduced treatment toxicity
Comprehensive Molecular Profiling
- Single test covering multiple actionable biomarkers
- Reduces need for sequential testing and tissue consumption
- Provides complete molecular picture for treatment decisions
Understanding Your Test Results
Your genetic test results will provide detailed information about the presence or absence of specific mutations:
Positive Results
- Indicates presence of targetable genetic alterations
- Your oncologist will discuss appropriate targeted therapy options
- May qualify for specific FDA-approved treatments
Negative Results
- No detectable mutations in the tested genes
- Alternative treatment approaches will be considered
- May indicate need for additional biomarker testing
Interpretation Guidance
- Results should always be discussed with your oncology team
- Genetic counseling may be recommended for complex findings
- Test results become part of your permanent medical record
Test Pricing and Availability
| Test Name | Discount Price | Regular Price |
|---|---|---|
| Lung Cancer Panel 3 EGFR ALK1 ROS1 MET | $750 USD | $1000 USD |
Test Specifications
- Turnaround Time: 5-7 business days
- Sample Type: Tumor tissue (paraffin embedded tissue blocks)
- Testing Methods: FISH and Sanger Sequencing
- Prescription Required: Doctor’s prescription needed (not applicable for surgery, pregnancy, or international travel cases)
Nationwide Testing Availability
We have diagnostic centers conveniently located across the United States, serving patients in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our network of certified laboratories ensures consistent, high-quality testing standards nationwide.
Take Action for Your Health
Don’t wait to get the comprehensive genetic information you need for optimal lung cancer treatment. Our experienced genetic counselors and oncology specialists are ready to assist you throughout the testing process.
Call or WhatsApp us today at +1(267) 388-9828 to schedule your Lung Cancer Panel 3 test and take the first step toward personalized cancer care.
Early genetic testing can make a significant difference in your treatment journey. Book your appointment now to access advanced molecular diagnostics and targeted treatment options tailored to your specific genetic profile.
